Pharma Investing in Biotech to Dampen Patent Cliff Fall

Washington Drug Letter
Orphan drug incentives, new technology and anxiety over expiring patents have dramatically spurred investment into biotech products, with the number of large molecule, biologic drugs in development tripling over the past decade.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00